Europe Ovarian Cancer Market - 2023-2030

Europe Ovarian Cancer Market - 2023-2030

Market Overview

The Europe ovarian cancer size was valued at US$ XX billion in 2022 and is estimated to reach US$ XX billion, growing at a CAGR of XX% during the forecast period (2023-2030).

Ovarian cancer is a deadly gynecological cancer and is the seventh most common cancer in women globally. Most women with ovarian cancer are diagnosed at the advanced stage, which is the most challenging to treat. Chemotherapy and Surgery are usually used in the treatment of ovarian cancer.

Market Dynamics

The major factors that drive the European ovarian cancer diagnostics and therapeutics market are the increasing geriatric women population, the rise in ovarian cancer cases, and the increasing use of combination therapies to treat ovarian cancer.

The growing cases of ovarian cancer and new product approvals are predicted to drive Europe’s market growth.

The researchers estimated that about 26,500 women died of ovarian cancer in EU countries in 2022 and over 4,000 in the UK. After modifying for distinctions in age dispersal in the population, the age-standardized rate of casualties was 4.32 and 4.57 women per 100,000 in the EU and UK, respectively. Moreover, the incidence of ovarian cancer is elevated in women aged 55 to 64. Also concerned with the article published by OCRA in May 2021, over two-thirds of ovarian cancer diagnosed cases are 55 years or older. The primary signs of ovarian cancer enclose bloating, pelvic and abdominal pain, difficulty eating, and urinary manifestations. According to NCBI's article published in February 2022, ovarian cancer is the fifth most ordinary cancer in Europe for females. Additionally, according to the GLOBOCAN estimates for 2020, Europe registered around 74,592 new ovarian cancer cases in 2020. With the growing load of cancer, there is an increased requirement for efficacious treatment.

In addition, European product authorizations are anticipated to contribute to market growth during the forecast period. For example, in May 2022, INEX Innovative obtained CE-IVD certification for its OvaCis Rapid Test for detecting cancer in ovarian cysts. Therefore, the growing cases of ovarian cancer among aging females in Europe and rising product approvals are estimated to drive the market in the forecast period.

The high cost of chronic ovarian cancer treatment in Europe is restraining the Europe Ovarian Cancer market growth.

However, the high cost of ovarian cancer treatment in Europe is hampering the market growth in the forecast period. For instance, the price of ovarian cancer treatment in Poland Laparoscopic hysterectomy in Polish clinics starts at 3,800 euros.

COVID-19 Impact.

The COVID-19 pandemic resulted in the significant reconfiguration of gynecologic cancer services and care pathways across the globe, with a transformation of working practices. Services had to adapt to protect vulnerable patients from infection while providing care despite reduced resources/capacity and staffing. The international gynecologic cancer community introduced modified clinical care guidelines. Remote working, reduced hospital visiting, routine COVID-testing, and use of COVID-free surgical areas/hubs enabled the ongoing and safe delivery of complex cancer care, with priority levels for cancer treatments established to guide decision-making by multidisciplinary tumor boards. Some 2.3 million cancer surgeries were delayed or canceled during the first peak, with many patients reporting significant anxiety/concern for cancer progression and COVID infection. Although COVID trials were prioritized, recruitment to other cancer trials/research activity was significantly reduced. The impact of resultant protocol deviations on outcomes remains to be established. During the recovery, healthcare services must maintain capacity and flexibility to manage future surges of infection, address the large backlog of patients with altered or delayed treatments, and salvage screening and prevention services.

Segment Analysis

Epithelial ovarian cancer is expected to have a greater grasp of the Ovarian Cancer market during the forecast period (2022-2029)

Epithelial ovarian cancer dominated the global market in 2021. It is expected to show a similar trend throughout the forecast period (2022-2029), as epithelial cancer is the most common type of ovarian cancer. A large number of clinical research is ongoing. For instance, according to Cancer Research UK, about 90 out of 100 tumors of the ovary (90%) are epithelial, and according to the ClinicalTrails.Gov, over 200 interventional studies are active for epithelial ovarian cancer examples of a few are a phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for treatment of relapse ovarian cancer, a phase II pharmacological study with Wee-1 inhibitor MK-1775 combined with carboplatin in patients with p53 mutated epithelial ovarian cancer and early relapse (< 3 months) or progression during standard first-line treatment, a GINECO phase II trial for the assessment of safety and the efficacy of the Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patients with advanced epithelial ovarian cancer in relapse, a phase 3, single-arm study of Mirvetuximab Soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression and many more. Thus, the increasing research on epithelial ovarian cancer and cases of epithelial cancer ensures the dominance of epithelial ovarian cancer over the Europe ovarian cancer market throughout the forecast period.

Geographical Analysis

The U.K is expected to be dominating the Europe ovarian cancer market.

The U.K is anticipated to show substantial growth in the forecast period owing to a high number of ovarian cancer cases registered in the country. Moreover, many clinical trials have been executed in the country. According to data publicized by GLOBOCAN 2020, the incidence of ovarian cancer in the U.K in 2020 was around 6,065 cases. These large incidences of ovarian cancer in the United States are expected to drive the growth of the studied market in the U.K. In addition, the evolution of ovarian diagnostics in the U.K is anticipated to contribute to the expansion of the market. For instance, in May 2022, the Universities of Manchester, Birmingham, and Exeter conducted a study to determine if human epididymis protein 4 (HE4), found in the blood, could assist in determining ovarian cancer more accurately and save other women from unnecessary and often invasive procedures such as biopsies and physical examinations. Such developments are expected to contribute to the market's growth during the forecast period in the U.K.

Furthermore, the availability of ovarian cancer therapeutics in the United States is predicted to push the market's growth. For instance, in January 2021, Zejula, marketed by Tesaro, was available in the U.K as maintenance therapy for advanced ovarian cancer. Thus, the abovementioned factors are expected to drive the market's growth during the U.K's forecast period.

Competitive Landscape

The key players operating in the Europe Ovarian Cancer market are AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline PLC, Johnson and Johnson, Amgen Inc., Amneal Pharmaceuticals, Siemens Healthineers AG, among others. The key players are embracing various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Ovarian Cancer market in Europe. For instance,

Amgen Inc.

Overview:

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and innovates novel medicines based on cellular and molecular biology advances.

Product Portfolio:

The company’s portfolio has Trebananib (AMG 386) TRINOVA-1.

The Europe ovarian cancer report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.